Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEurocell Regulatory News (ECEL)

Share Price Information for Eurocell (ECEL)

Share Price is delayed by 15 minutes
Get Live Data
109.50    2.00 (1.86%)
Bid:
105.50
Ask:
106.50
Spread: 1.00 (0.948%)
Market Cap: £107.91m
ECEL Live PriceLast checked at - London Stock Exchange

Intraday Eurocell Share Chart

Year End Trading Update

22 Jan 2026 07:00

RNS Number : 8432P
Eurocell plc
22 January 2026
 

22 January 2026

EUROCELL PLC

("Eurocell" the "Group" or the "Company")

Year End Trading Update - Performance In Line With Expectations

 

Eurocell plc, the leading UK manufacturer and distributor of window and door products to the trade, provides the following update for the year ended 31 December 2025.

 

Summary

We expect sales and adjusted profit before tax for the year ended 31 December 2025 to be in line with expectations (subject to audit).

 

Trading conditions have remained subdued, with challenging macroeconomic conditions and weak consumer confidence continuing to impact both the repair, maintenance and improvement market (RMI) and new build housing. These trends were compounded in the fourth quarter of the year, with increasing uncertainty over the Autumn Budget announcements driving a further slowdown.

 

Group revenues for 2025 were up 13%, enhanced by the acquisition of Alunet in March, which continues to perform strongly. Organic revenues for the year were level with 2024, due to further progress of our growth strategy, which we are pleased to see coming through in the sales performance of our key initiatives.

 

We have faced ongoing competitive pressure on selling prices in the branches, as well as overhead cost inflation across the business. Our focus remains on further operational improvements and cost reduction initiatives to drive greater efficiencies and to mitigate against the impact of weaker markets.

 

Trading Performance

Group sales for the year ended 31 December 2025 were £403.6 million, up 13% on 2024, or flat excluding Alunet, with organic volumes 2% lower. Comparisons by division are:

 

Sales for the year ended31 December 2025

vs 2024

Profiles Division

+1%

Branch Network Division

-1%

Group, excluding Alunet

Flat

Total Group, including Alunet

+13%

 

· Profiles division sales up 1% on 2024, with volumes 2% lower, reflecting:

- Reduced RMI activity through our trade fabricators, partially offset by some modest improvement in the new build housing market

· Branch Network division sales down 1% on 2024, with volumes 2% lower, reflecting:

- General Branch Network sales to the RMI market down 6%

- Offset by further progress with our strategic initiatives, including window and door sales up 12% on 2024 (and up 26% on 2023, the base year for our strategic plan). In addition, compared to 2024, garden rooms were up 9% and e-commerce activity up 40%, with the sales to date from new branches at £3.3 million

· Alunet post-acquisition sales were £46.7 million, representing growth of 28% over the corresponding period in 2024, driven by market share gains

- Alunet Systems is benefiting from Group synergies, securing new business with 14 existing Eurocell fabricators

- Comp Door is continuing to acquire new installers, with the new Sleekskin door being well received by the trade 

- Improved performance from JDUK, which recovered market share in garage doors

 

We continue to focus on efficient working capital management and delivered solid cash flow generation in 2025. As a result, we expect pre-IFRS 16 net debt to be in the region of £22 million at 31 December 2025, down from £29 million at 30 June 2025, and representing leverage of 0.7x pre-IFRS 16 EBITDA, ahead of our previous guidance of 0.9x.

 

Capital Allocation

In line with our strategy, significant investments in the next 12 months include delivering the project to modernise our IT infrastructure, where we expect to transition in the second half of 2026, and further new branch openings.

 

We are committed to driving shareholder returns through a combination of ordinary dividends and supplementary distributions (currently via share buybacks) where appropriate.

 

Under the £5 million share buyback announced in March 2025, we have now purchased approximately 3.1 million ordinary shares at a cost of £4.5 million, and we expect to complete this buyback in February. Thereafter, as previously reported, we intend to continue share buybacks, subject to maintaining a strong financial position.

 

Notice of Results

We expect to publish our results for the year ended 31 December 2025 on 19 March 2026, at which time we will provide further guidance on the year ahead.

 

 

Enquiries:

Eurocell plc

Darren Waters, Chief Executive Officer +44 (0) 1773 842 105

Michael Scott, Chief Financial Officer +44 (0) 1773 842 140

 

Teneo

Nick de Bunsen +44 (0) 7825 575 258

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQFLFLQFLZBBD
Date   Source Headline
18th May 20264:00 pmRNSDirector/PDMR Shareholding
14th May 20261:49 pmRNSResult of AGM
14th May 20267:00 amRNSTrading Update
1st May 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSLeadership Update - CFO Appointment
15th Apr 20267:00 amRNSPublication of 2025 Annual Report & Notice of AGM
23rd Mar 202610:15 amRNSDirector/PDMR Shareholding
19th Mar 202610:30 amRNSDirector/PDMR Shareholding
19th Mar 20267:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2025
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSTransaction in Own Shares - Buyback Complete
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20261:00 pmRNSDirectorate changes
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSDirector/PDMR Shareholding
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTransaction in Own Shares
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSYear End Trading Update
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20254:00 pmRNSPurchase of Shares via Employee Benefit Trust
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.